when does tirzepatide patent expire expiry expiration eli lilly Tirzepatide's primary patents in 2036 but Eli Lilly has Canada approves generic semaglutide from

This article compares what trials have documented across mechanism, weight-loss outcomes, glycemic effects, cardiovascular outcomes, side-effect profile, cost, and regulatory status

Weight loss was similarly enhanced, with tirzepatide 15 mg producing a mean reduction of 11.2 kg compared to 5.7 kg with semaglutide

This is likely to lead to weight gain over time

The most commonly reported adverse effects were gastrointestinal in nature , including: Nausea Vomiting Diarrhoea Constipation Decreased appetite These effects were generally mild to moderate in severity, most prevalent during dose escalation, and tended to diminish over time